Telomerase activity in plasma cell dyscrasias

被引:0
|
作者
D Xu
C Zheng
S Bergenbrant
G Holm
M Björkholm
Q Yi
A Gruber
机构
[1] Karolinska Hospital,Department of Medicine, Division of Hematology
[2] University of Arkansas for Medical Sciences,Myeloma and Transplantation Research Center
来源
British Journal of Cancer | 2001年 / 84卷
关键词
hTERT; multiple myeloma; plasma cells; telomerase;
D O I
暂无
中图分类号
学科分类号
摘要
Activation of telomerase is essential for in vitro cellular immortalization and tumorigenesis. In the present study, we investigated telomerase activation and its implications in plasma cell dyscrasias including monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and plasma cell leukaemia (PCL). All 5 patients with MGUS exhibited normal levels of telomerase activity in their plasma cells. Elevated telomerase activity was found in the samples from 21/27 patients with MM and 4/4 with PCL. In addition, 4 myeloma cell lines all expressed high levels of telomerase activity. The expression of telomerase reverse transcriptase (hTERT) and telomerase RNA template (hTER) was positively associated with the levels of telomerase activity in MM/PCL. Tankyrase expression was upregulated, concomitant with the induction of hTERT and activation of telomerase in MM/PCL. The present findings indicate that MGUS cells may not be immortalized and that activation of telomerase plays a role in the malignant transformation from MGUS to MM. © 2001 Cancer Research Campaign
引用
收藏
页码:621 / 625
页数:4
相关论文
共 50 条
  • [41] MONOCLONAL IMMUNOGLOBULINS WITH ANTIBODY-ACTIVITY IN MYELOMA, MACROGLOBULINEMIA AND RELATED PLASMA-CELL DYSCRASIAS
    MERLINI, G
    FARHANGI, M
    OSSERMAN, EF
    SEMINARS IN ONCOLOGY, 1986, 13 (03) : 350 - 365
  • [42] Plasma Cell Dyscrasias in India-2017 Updates
    Jain, Arihant
    Malhotra, Pankaj
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (01) : 1 - 4
  • [43] ANION GAP IN ASYMPTOMATIC PLASMA-CELL DYSCRASIAS
    SCHNUR, MJ
    APPEL, GB
    KARP, G
    OSSERMAN, EP
    ANNALS OF INTERNAL MEDICINE, 1977, 86 (03) : 304 - 305
  • [44] Azotemia associated with use of lenalidomide in plasma cell dyscrasias
    Batts, Eric D.
    Sanchorawala, Vaishali
    Hegerfeldt, Yael
    Lazarus, Hillard M.
    LEUKEMIA & LYMPHOMA, 2008, 49 (06) : 1108 - 1115
  • [45] The role of CD81 for plasma cell dyscrasias
    Binder, Mascha
    Bacher, Ulrike
    LEUKEMIA RESEARCH, 2014, 38 (03) : 292 - 293
  • [46] Multicolor interphase cytogenetics for the study of plasma cell dyscrasias
    Saez, Borja
    Martin-Subero, Jose I.
    Odero, Maria D.
    Prosper, Felipe
    Cigudosa, Juan C.
    Schoch, Robert
    Calasanz, Maria J.
    Siebert, Reiner
    ONCOLOGY REPORTS, 2007, 18 (05) : 1099 - 1106
  • [47] POLYCLONAL IMMUNOGLOBULINS IN MALIGNANT PLASMA-CELL DYSCRASIAS
    BATAILLE, R
    DESSAUW, P
    SANY, J
    ONCOLOGY, 1984, 41 (05) : 314 - 317
  • [48] TEST YOUR KNOWLEDGE OF PLASMA-CELL DYSCRASIAS
    FARHANGI, M
    DRUG THERAPY HOSPITAL EDITION, 1977, 2 (10): : 26 - 27
  • [49] Successful treatment of rare plasma cell dyscrasias with lenalidomide
    Besemer, B.
    Oehrlein, K.
    Bross-Bach, U.
    Weisel, K.
    Kanz, L.
    ONKOLOGIE, 2011, 34 : 161 - 161
  • [50] Aberrant gene promoter methylation in plasma cell dyscrasias
    Martin, Palorna
    Garcia-Cosio, Monica
    Santon, Almudena
    Bellas, Carmen
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2008, 84 (03) : 256 - 261